Form 10-Q Epizyme, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
RBC Affirms Epizyme (EPZM) at 'Outperform' as Ttazemetostat Enrollment Continues
November 9, 2015 12:43 PM ESTRBC Captial affirms Epizyme (Nasdaq: EPZM) at Outperform with a price target of $39 following Q3 results and update issued earlier.
Analyst Simos Simeonidis noted the following:
Enrollment continues in 150-patient Phase II study in NHL in Europe: On their 3Q15 earnings call this morning, management stated that plans remain on track for tazemetostat's Phase II programs. Patients are currently being enrolled in the 5-arm,... More
